New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export SNY’s income statement to Excel — free account
Sanofi
SNYHealthcare Drug Manufacturers General
Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- +8.21%
- Free cash flow
- +99.6%
- Total debt
- −11.2%
Quarter to September 2026, against a year earlier
46.62
0.56
+1.22%
Follow SNY
Alert me
Where the cash went Fiscal 2025, year to Dec 31, 2025
Dividends and buybacks of $10.9B were more than free cash flow of $9.1B; $1.7B of new borrowing made up the difference. Cash rose by $244.4M. What is a cash flow statement?
- Free cash flow
- $9.1B 75.0% of operating cash flow
- Returned to shareholders
- $10.9B 119.9% of free cash flow
- Debt, net
- $1.7B borrowed
- Change in cash
- +$244.4M over the period
| Operating cash flow | 12.2 |
|---|---|
| Capital expenditures | −3.0 |
| Free cash flow | 9.1 |
| Acquisitions, net | +11.8 |
| Into investments, net | −11.4 |
| Dividends | −5.4 |
| Buybacks, net | −5.5 |
| Debt raised, net | +1.7 |
| Change in cash | 0.2 |
Free cash flow
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $8.7B | $8.3B | $6.6B | $8.7B | $8.5B | $12.4B | $11.1B | $11.1B | $9.8B | $12.2B |
| Capex | −$2.1B | −$1.6B | $220M | −$663M | −$1.4B | −$1.6B | −$751M | −$2.2B | −$1.9B | −$3.0B |
| Free cash flow | $6.6B | $6.7B | $6.8B | $8.0B | $7.1B | $10.9B | $10.3B | $8.9B | $8.0B | $9.1B |
Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Net Income |
5,587.98 | 5,947.22 | 5,844.42 | 8,819.69 | 7,362.43 | 14,066.28 | 3,142.72 | 5,085.39 | 9,532.95 | 5,210.98 |
Depreciation & Amortization |
6,424.09 | 3,880.41 | 5,186.38 | 3,603.31 | 3,964.57 | 4,208.23 | 8,346.24 | 5,053.50 | 4,166.29 | 3,652.89 |
Non Cash Items (Other) |
(1,767.25) | 664.41 | (755.45) | (882.92) | (477.97) | (8,582.10) | (2,346.40) | (2,076.20) | (5,526.04) | (1,106.60) |
Accounts Receivable Change |
(1,359.94) | (30.30) | (429.67) | (818.65) | 218.87 | (153.07) | (517.44) | (41.33) | (597.93) | 185.91 |
Change in inventories |
(44.12) | (516.16) | (909.13) | (976.69) | (422.37) | (677.38) | (612.64) | (827.88) | (163.89) | (357.43) |
Accounts Payable Change |
450.30 | 853.78 | 435.08 | 476.23 | 533.58 | 98.24 | 189.28 | 318.87 | 652.18 | 494.65 |
Change in other assets and liabilities |
2,871.49 | (972.81) | 1,730.60 | 869.22 | 1,269.47 | (451.21) | 471.52 | (961.33) | 276.92 | 593.14 |
Operating Cash Flow |
12,162.55 | 9,826.55 | 11,102.23 | 11,090.19 | 12,448.58 | 8,508.99 | 8,673.28 | 6,551.01 | 8,340.48 | 8,673.53 |
Capital expenditures |
(3,044.60) | (1,876.36) | (2,174.34) | (751.22) | (1,567.61) | (1,366.19) | (663.04) | 219.67 | (1,606.16) | (2,073.77) |
Net Aquisitions |
11,768.82 | (117.95) | — | (1,055.32) | (6,356.82) | 11,845.65 | (556.18) | (14,866.67) | (1,431.33) | (460.00) |
Short Term Investments Change (Net) |
— | — | — | — | (80.45) | (129.08) | (105.28) | (68.50) | (184.24) | (3.32) |
Long-Term Investments Change (Net) |
(11,402.25) | (2,731.22) | (4,288.07) | (1,418.15) | (6,986.21) | (6,251.81) | (589.12) | (15,345.91) | (1,482.95) | (701.58) |
Other investing activities |
(90.51) | (43.28) | (247.85) | (16.86) | (54.55) | (54.32) | 51.69 | (89.66) | 3,924.10 | (42.11) |
Investing cash flow |
(2,768.54) | (4,768.81) | (6,710.26) | (2,186.22) | (8,634.26) | 4,098.57 | (1,357.44) | (15,194.75) | (3,273.35) | (2,778.67) |
Repayment/Issuance of Debt (Net) |
1,701.63 | (967.40) | (3,394.09) | (1,311.73) | (3,317.41) | (2,153.24) | (549.92) | 10,300.68 | (2,596.30) | 2,537.43 |
Equity Repurchase (Common, Net) |
(5,490.68) | (124.44) | (430.76) | (325.56) | (231.89) | (707.08) | 171.36 | (1,091.24) | (2,083.14) | (2,880.48) |
Dividends Paid (Total) |
(5,442.03) | (5,131.32) | (4,886.58) | (4,495.71) | (4,798.65) | (4,547.50) | (4,309.76) | (4,472.45) | (4,210.37) | (4,182.95) |
Other financial activities |
(54.31) | (12.99) | (3.25) | (359.57) | 88.64 | (9,425.93) | (7.84) | (90.94) | (41.82) | (12.17) |
Financing cash flow |
(9,285.40) | (6,236.14) | (8,714.68) | (6,133.00) | (8,347.95) | (7,407.81) | (4,696.16) | 4,646.05 | (8,931.63) | (4,538.17) |
Exchange Rate Adjustment |
(53.18) | (14.07) | (34.63) | 8.43 | 17.75 | (73.11) | 10.08 | 1.18 | (83.64) | (111.77) |
Discontinued Operations and Adjustments |
188.94 | (180.71) | — | — | — | — | 172.48 | (7.09) | 3,995.61 | — |
Change in Cash |
244.38 | (1,373.18) | (4,357.34) | 2,779.40 | (4,515.89) | 5,126.64 | 2,802.24 | (4,003.59) | 47.47 | 1,244.93 |
Beginning Cash |
8,418.75 | 9,425.09 | 13,784.17 | 10,639.25 | 16,462.84 | 10,768.46 | 7,756.00 | 12,182.01 | 11,611.57 | 10,123.18 |
Ending Cash |
8,663.13 | 8,051.91 | 9,426.83 | 13,418.65 | 11,946.94 | 15,895.10 | 10,558.24 | 8,178.43 | 11,659.04 | 11,368.10 |
Dividends Paid (Common) |
(5,442.03) | (5,131.32) | (4,886.58) | (4,495.71) | (4,798.65) | (4,547.50) | (4,309.76) | (4,472.45) | (4,210.37) | (4,182.95) |
Net Cash/Marketcap |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Assets Liabilities Change (Total) |
1,917.72 | (665.49) | 826.88 | (449.89) | 1,599.55 | (1,183.42) | (469.28) | (1,511.68) | 167.28 | 916.26 |
Investments Change (Net) |
(11,402.25) | (2,731.22) | (4,288.07) | (1,418.15) | (7,066.66) | (6,380.89) | (694.40) | (15,414.41) | (1,667.19) | (704.90) |
Issuance/Purchase of Shares |
(5,490.68) | (124.44) | (430.76) | (325.56) | (231.89) | (707.08) | 171.36 | (1,091.24) | (2,083.14) | (2,880.48) |
| Other line items | ||||||||||
Revenue per Employee |
0.71 | 0.58 | 0.58 | 0.52 | 0.49 | 0.43 | 0.42 | 0.40 | 0.38 | 0.36 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 5, 2026